Ultragenyx Pharmaceutical (RARE) EBITDA: 2016-2025
Historic EBITDA for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$170.9 million.
- Ultragenyx Pharmaceutical's EBITDA fell 29.47% to -$170.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$544.0 million, marking a year-over-year decrease of 1.54%. This contributed to the annual value of -$536.0 million for FY2024, which is 5.84% up from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its EBITDA stood at -$170.9 million for Q3 2025, which was down 58.40% from -$107.9 million recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's EBITDA ranged from a high of -$82.8 million in Q2 2021 and a low of -$225.1 million during Q3 2022.
- Moreover, its 3-year median value for EBITDA was -$142.9 million (2025), whereas its average is -$138.8 million.
- Its EBITDA has fluctuated over the past 5 years, first tumbled by 150.55% in 2022, then surged by 35.53% in 2023.
- Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's EBITDA stood at -$102.6 million in 2021, then crashed by 41.99% to -$145.6 million in 2022, then climbed by 16.19% to -$122.0 million in 2023, then declined by 0.19% to -$122.3 million in 2024, then declined by 29.47% to -$170.9 million in 2025.
- Its EBITDA was -$170.9 million in Q3 2025, compared to -$107.9 million in Q2 2025 and -$142.9 million in Q1 2025.